Everolimus-induced tubular toxicity in non-renal cancer

Intern Med J. 2016 Dec;46(12):1454-1455. doi: 10.1111/imj.13284.

Authors

S Chan^{1

2

3}, L P Francis⁴, A L Kark^{2

3}, K J Bigby^{1

3}, H G Healy², B W Chern^{1

3}

Affiliations

¹ Cancer Care Services, Redcliffe Hospital, Brisbane, Queensland, Australia.
² Kidney Health Service, Royal Brisbane and Women's Hospital, Metro North Hospital Health Service, Brisbane, Queensland, Australia.
³ School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
⁴ Department of Pathology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

PMID: 27981761
DOI: 10.1111/imj.13284

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Hormonal / therapeutic use
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary*
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Chemoradiotherapy / methods
Everolimus / adverse effects*
Everolimus / therapeutic use
Female
Hip / pathology*
Humans
Kidney Diseases / chemically induced*
Kidney Tubules, Proximal / drug effects*
Mastectomy
Middle Aged
Neoplasm Recurrence, Local
Tamoxifen / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Antineoplastic Agents, Hormonal
Tamoxifen
Everolimus